2024-07-12 04:00:13
Currently, ketamine can only be administered to patients under medical supervision in a hospital, and as of March 2019, it was administered intravenously at a hospital in Palo Alto (California).
Whether administered intravenously or as a nasal spray, ketamine (an anesthetic that has been used for years in veterinary surgeries as well as an analgesic) has been shown to be effective in treating patients with treatment-resistant depression, that is, in at least two In cases where drug treatment fails, there are eight years to a few weeks. Its management is strictly supervised. Perform in hospital and under supervision due to possible adverse effects: dissociation, altered perception, transient increase in blood pressure.
A new delivery method in the form of extended-release oral tablets might be a game-changer. A randomized, double-blind phase 2 study evaluated this treatment in patients with severe depression (Montgomery-Asberg Depression Rating Scale (MADRS) score between 20 and 30) who had received an average of 4.8 prior antidepressants. The efficacy and safety of the treated subjects were conducted without success. The result appears in natural medicine June 24th.
The study was conducted at 20 institutions in Australia, New Zealand, Taiwan and Singapore and was divided into two phases. First, 231 subjects were given ketamine tablets at a dose of 120 milligrams (mg) per day for five days and were then evaluated eight days later. Researchers select patients who responded So far, the failure rate of the first treatment has been reduced to 168 people. The subjects were then divided into five groups, each given different doses of placebo or ketamine tablets of 30 mg, 60 mg, 120 mg or 180 mg twice a week for 12 weeks. Subjects carried their tablets at home.
Side effects are relatively weak
At the end of this period, the results seemed promising. “The mean reduction in MADRS was greater across all treatment groups compared to the group receiving placebo. The greatest effect was observed in patients receiving the 180 mg dose, who experienced a mean score decrease of 6.1 points compared to the placebo group.Paul Glue, professor of psychiatry at the University of Otago in New Zealand, emphasized. Other reassuring news: Tolerability of treatment. Most side effects (dizziness, headache, euphoria, dissociation, nausea, etc.) are mostly quite mild. Ten serious adverse events were recorded, including one suicide, but the authors noted that none were related to treatment. Furthermore, no changes in blood pressure were observed.
There are 26.19% of this article left to read. The remainder is reserved for subscribers.
1721623865
#Ketamine #tablets #promising #avenue
